000			01921 a2200577 4500
005			20250513224128.0
264		0	_c20010104
008			200101s 0 0 eng d
022			_a0014-4886
024	7		_a10.1006/exnr.2000.7516 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoussaoui, S
245	0	0	_aThe antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. _h[electronic resource]
260			_bExperimental neurology _cDec 2000
300			_a235-45 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_a1-Methyl-4-phenylpyridinium _xpharmacokinetics
650	0	4	_aAnimals
650	0	4	_aAntioxidants _xpharmacology
650	0	4	_aAzoles _xpharmacology
650	0	4	_aBehavior, Animal _xdrug effects
650	0	4	_aBlood Proteins _xpharmacology
650	0	4	_aCallithrix
650	0	4	_aCaudate Nucleus _xmetabolism
650	0	4	_aDisease Models, Animal
650	0	4	_aFemale
650	0	4	_aFree Radicals _xmetabolism
650	0	4	_aGlutathione Peroxidase _xmetabolism
650	0	4	_aHerbicides _xpharmacokinetics
650	0	4	_aIsoindoles
650	0	4	_aLocomotion _xdrug effects
650	0	4	_aMale
650	0	4	_aMitochondria _xdrug effects
650	0	4	_aMolecular Mimicry
650	0	4	_aNeurons _xcytology
650	0	4	_aNeuroprotective Agents _xpharmacology
650	0	4	_aOrganoselenium Compounds _xpharmacology
650	0	4	_aPC12 Cells
650	0	4	_aParkinsonian Disorders _xdrug therapy
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aSubstantia Nigra _xmetabolism
650	0	4	_aTritium
700	1		_aObinu, M C
700	1		_aDaniel, N
700	1		_aReibaud, M
700	1		_aBlanchard, V
700	1		_aImperato, A
773	0		_tExperimental neurology _gvol. 166 _gno. 2 _gp. 235-45
856	4	0	_uhttps://doi.org/10.1006/exnr.2000.7516 _zAvailable from publisher's website
999			_c11027538 _d11027538